Prelude Capital Management’s Alpine Immune Sciences Inc ALPN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-27,100
Closed -$1.07M 1577
2024
Q1
$1.07M Sell
27,100
-14,400
-35% -$425K 0.06% 379
2023
Q4
$791K Buy
+41,500
New +$577K 0.05% 362
2015
Q4
Sell
-75
Closed -$4K 1737
2015
Q3
$4K Buy
+75
New +$4.93K ﹤0.01% 1409

Prelude Capital Management's ALPN Position: Q2 2024 in Review

Prelude Capital Management sold out of Alpine Immune Sciences Inc (ALPN) in Q2 2024, closing a stake of 27,100 shares — an estimated $1.07M sold.

Prelude Capital Management first reported a position in ALPN in Q3 2015 and held it in 3 quarters. The position peaked at $1.07M in Q1 2024. 0 funds tracked by Wall St. Rank hold ALPN as of Q2 2024.

  • Prelude Capital Management reported no remaining Alpine Immune Sciences Inc position as of Q2 2024 after selling out during the quarter.
  • Prelude Capital Management sold 27,100 Alpine Immune Sciences Inc shares in Q2 2024, an estimated $1.07M.
  • Prelude Capital Management first reported a position in Alpine Immune Sciences Inc in Q3 2015 and held it in 3 quarters.
  • Prelude Capital Management's Alpine Immune Sciences Inc position peaked at $1.07M in Q1 2024.
  • 0 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q2 2024.

Based on Prelude Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.